JP2023024574A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023024574A5 JP2023024574A5 JP2022202809A JP2022202809A JP2023024574A5 JP 2023024574 A5 JP2023024574 A5 JP 2023024574A5 JP 2022202809 A JP2022202809 A JP 2022202809A JP 2022202809 A JP2022202809 A JP 2022202809A JP 2023024574 A5 JP2023024574 A5 JP 2023024574A5
- Authority
- JP
- Japan
- Prior art keywords
- varenicline
- pharmaceutically acceptable
- acceptable salt
- medicament
- micrograms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 31
- 150000003839 salts Chemical class 0.000 claims 18
- JQSHBVHOMNKWFT-DTORHVGOSA-N varenicline Chemical compound C12=CC3=NC=CN=C3C=C2[C@H]2C[C@@H]1CNC2 JQSHBVHOMNKWFT-DTORHVGOSA-N 0.000 claims 18
- 229960004751 varenicline Drugs 0.000 claims 18
- 210000003928 nasal cavity Anatomy 0.000 claims 3
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 2
- 206010052143 Ocular discomfort Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 238000002483 medication Methods 0.000 claims 2
- 239000007922 nasal spray Substances 0.000 claims 2
- 229940097496 nasal spray Drugs 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 230000004489 tear production Effects 0.000 claims 2
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 1
- 241000021559 Dicerandra Species 0.000 claims 1
- 206010065062 Meibomian gland dysfunction Diseases 0.000 claims 1
- 235000010654 Melissa officinalis Nutrition 0.000 claims 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 claims 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 claims 1
- 206010034960 Photophobia Diseases 0.000 claims 1
- 208000003251 Pruritus Diseases 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 1
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 1
- 208000010217 blepharitis Diseases 0.000 claims 1
- 230000008499 blood brain barrier function Effects 0.000 claims 1
- 210000001218 blood-brain barrier Anatomy 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 210000000744 eyelid Anatomy 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 230000007794 irritation Effects 0.000 claims 1
- 230000007803 itching Effects 0.000 claims 1
- 239000000865 liniment Substances 0.000 claims 1
- 238000002690 local anesthesia Methods 0.000 claims 1
- 239000006210 lotion Substances 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 230000036407 pain Effects 0.000 claims 1
- 239000006072 paste Substances 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000011514 reflex Effects 0.000 claims 1
- 230000035807 sensation Effects 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 230000001988 toxicity Effects 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 claims 1
- 210000003901 trigeminal nerve Anatomy 0.000 claims 1
- 239000006200 vaporizer Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462066280P | 2014-10-20 | 2014-10-20 | |
| US62/066,280 | 2014-10-20 | ||
| US201562100844P | 2015-01-07 | 2015-01-07 | |
| US62/100,844 | 2015-01-07 | ||
| JP2020193269A JP7257371B2 (ja) | 2014-10-20 | 2020-11-20 | 眼の病状の治療方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020193269A Division JP7257371B2 (ja) | 2014-10-20 | 2020-11-20 | 眼の病状の治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023024574A JP2023024574A (ja) | 2023-02-16 |
| JP2023024574A5 true JP2023024574A5 (https=) | 2023-09-25 |
| JP7502404B2 JP7502404B2 (ja) | 2024-06-18 |
Family
ID=55748136
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017539528A Active JP6873906B2 (ja) | 2014-10-20 | 2015-10-19 | 眼の病状の治療方法 |
| JP2020193269A Active JP7257371B2 (ja) | 2014-10-20 | 2020-11-20 | 眼の病状の治療方法 |
| JP2022202809A Active JP7502404B2 (ja) | 2014-10-20 | 2022-12-20 | 眼の病状の治療方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017539528A Active JP6873906B2 (ja) | 2014-10-20 | 2015-10-19 | 眼の病状の治療方法 |
| JP2020193269A Active JP7257371B2 (ja) | 2014-10-20 | 2020-11-20 | 眼の病状の治療方法 |
Country Status (21)
| Country | Link |
|---|---|
| US (14) | US9532944B2 (https=) |
| EP (3) | EP3209295B2 (https=) |
| JP (3) | JP6873906B2 (https=) |
| KR (2) | KR102511955B1 (https=) |
| CN (3) | CN111956803B (https=) |
| AU (2) | AU2015336216B2 (https=) |
| BR (2) | BR122022025737B1 (https=) |
| CA (1) | CA2965129C (https=) |
| DK (2) | DK3848028T5 (https=) |
| EA (1) | EA035335B1 (https=) |
| ES (2) | ES2848977T5 (https=) |
| FI (1) | FI3848028T3 (https=) |
| IL (3) | IL293188B2 (https=) |
| MX (2) | MX392383B (https=) |
| MY (1) | MY186870A (https=) |
| PH (1) | PH12017500602A1 (https=) |
| PL (1) | PL3848028T3 (https=) |
| PT (2) | PT3209295T (https=) |
| SG (2) | SG10202011669PA (https=) |
| WO (1) | WO2016064759A1 (https=) |
| ZA (1) | ZA201703467B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10202011669PA (en) | 2014-10-20 | 2020-12-30 | Oyster Point Pharma Inc | Methods of treating ocular conditions |
| CN109310692B (zh) * | 2016-04-07 | 2022-01-25 | 奥伊斯特普安生物制药公司 | 治疗眼部病状的方法 |
| TW202019417A (zh) * | 2018-07-10 | 2020-06-01 | 美商奧伊斯特普安生物製藥公司 | 治療眼部症狀之正向異位調節劑與菸鹼乙醯膽鹼受體促效劑之組合 |
| TW202019424A (zh) * | 2018-07-10 | 2020-06-01 | 美商奧伊斯特普安生物製藥公司 | 治療眼部症狀之方法 |
| ES3039903T3 (en) * | 2020-04-28 | 2025-10-27 | Oyster Point Pharma Inc | Local administration of nicotinic acetylcholine receptor agonists for the inhibition of coronavirus infections |
| WO2025037323A1 (en) * | 2023-08-12 | 2025-02-20 | Pavan Kumar Kothapuvari | Pharmaceutical compositions for treatment of dry eye disease and associated disorders |
| DE102023208057A1 (de) * | 2023-08-23 | 2025-02-27 | Ursapharm Arzneimittel Gmbh | Ophthalmologische zusammensetzung enthaltend mindestens einen nikotinischen acetylcholinrezeptor-agonist zur topischen applikation am auge bei der prävention oder behandlung von entzündungen am auge |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6277855B1 (en) * | 2000-04-21 | 2001-08-21 | Inspire Pharmaceuticals, Inc. | Method of treating dry eye disease with nicotinic acetylcholine receptor agonists |
| US20030008892A1 (en) | 2001-07-09 | 2003-01-09 | Pfizer Inc. | Pharmaceutical composition and method of modulating cholinergic function in a mammal |
| EP1461040B1 (en) | 2001-11-29 | 2006-03-15 | Pfizer Products Inc. | Succinic acid salts of 5,8,14-triazatetracyclo[10.3.1.0 2,11 .0 4,9 ]-hexadeca-2(11),3,5,7,9,-pentaene and pharmaceutical compositions thereof |
| WO2004039366A1 (en) * | 2002-11-01 | 2004-05-13 | Pharmacia & Upjohn Company Llc | Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy |
| US20060270592A1 (en) * | 2004-03-19 | 2006-11-30 | Ophthalmic Research Associates, Inc. | Use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions |
| MX2007004495A (es) * | 2004-10-15 | 2007-05-10 | Pfizer Prod Inc | Composiciones y procedimientos para la administracion intranasal, bucal, sublingual y pulmonar de vareniclina. |
| EP1929996B1 (en) * | 2004-11-09 | 2011-02-16 | Novagali Pharma S.A. | Ophthalmic emulsions containing an immunosuppressive agent |
| WO2006100075A2 (en) * | 2005-03-22 | 2006-09-28 | Niconovum Ab | Use of an artificial sweetener to enhance absorption of nicotine |
| US20110086086A1 (en) | 2005-07-26 | 2011-04-14 | Pfizer Inc | Transdermal system for varenicline |
| CA2620202C (en) | 2005-08-26 | 2016-10-04 | The Board Of Trustees Of The Leland Stanford Junior University | Therapy procedure for drug delivery for trigeminal pain |
| US8182840B2 (en) | 2005-09-27 | 2012-05-22 | Tissue Tech, Inc. | Amniotic membrane preparations and purified compositions and therapy for scar reversal and inhibition |
| TWI405763B (zh) | 2006-11-02 | 2013-08-21 | Targacept Inc | 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺 |
| US20080132475A1 (en) * | 2006-12-05 | 2008-06-05 | Charles Gerald Connor | Treatment for dry eye |
| AU2008211613B2 (en) * | 2007-02-02 | 2013-05-23 | Pfizer Products Inc. | Tricyclic compounds and their use as glucocorticoid receptor modulators |
| EP2322168A1 (en) * | 2007-04-02 | 2011-05-18 | Parkinson's Institute | Methods and Compositions for Reduction of Side Effects of Therapeutic Treatments |
| US20090093446A1 (en) | 2007-10-05 | 2009-04-09 | Winston Laboratories, Inc. | Method for alleviating keratoconjunctivitis sicca |
| CL2008003507A1 (es) * | 2007-11-26 | 2009-11-27 | Neuroderm Ltd | Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico. |
| US20090215787A1 (en) | 2008-02-22 | 2009-08-27 | Mai De Ltd. | Preparations of new polymorphic forms of varenicline tartrate |
| JP2011513421A (ja) | 2008-03-05 | 2011-04-28 | ターガセプト，インコーポレイテッド | サブタイプ選択的なジアザビシクロアルカンのアミド |
| WO2010028033A1 (en) | 2008-09-05 | 2010-03-11 | Targacept, Inc. | Amides of diazabicyclooctanes and uses thereof |
| WO2010028011A1 (en) | 2008-09-05 | 2010-03-11 | Targacept, Inc. | Amides of diazabicyclononanes and uses thereof |
| PL3279195T3 (pl) | 2008-12-01 | 2020-12-14 | Oyster Point Pharma, Inc. | Synteza i nowe postacie soli (R)-5-((E)-2-pirolidyn-3-ylowinylo)pirymidyny |
| US9145396B2 (en) | 2008-12-01 | 2015-09-29 | Targacept, Inc. | Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine |
| GB2470833B (en) | 2009-06-03 | 2011-06-01 | Amira Pharmaceuticals Inc | Polycyclic antagonists of lysophosphatidic acid receptors |
| US20110274628A1 (en) | 2010-05-07 | 2011-11-10 | Borschke August J | Nicotine-containing pharmaceutical compositions |
| US8821457B2 (en) * | 2010-09-08 | 2014-09-02 | Johnson & Johnson Vision Care, Inc. | Punctal plug containing drug formulation |
| US20140170157A1 (en) * | 2011-06-15 | 2014-06-19 | Glaxosmithkline Intellectual Property (No.2) Limited | Method of selecting therapeutic indications |
| KR20140027939A (ko) * | 2011-06-30 | 2014-03-07 | 도레이 카부시키가이샤 | 지양제 |
| JP6162705B2 (ja) * | 2011-10-20 | 2017-07-12 | ノバルティス アーゲー | アルファ７ニコチン性アセチルコリン受容体活性化剤による処置に対する応答性を予測するバイオマーカー |
| CN104094114A (zh) * | 2011-11-30 | 2014-10-08 | 黛尔格诺斯蒂尔有限公司 | 干眼诊断 |
| ES2426517B1 (es) * | 2012-04-20 | 2014-05-14 | Genetracer Biotech S.L | Método para predecir la seguridad de un tratamiento farmacológico |
| ES2649730T3 (es) | 2013-03-15 | 2018-01-15 | Glia Llc | Distribución craneal de compuestos farmacéuticos |
| EP2986339A4 (en) | 2013-04-19 | 2016-12-21 | Oculeve Inc | Nasal stimulation devices and methods |
| SG10202011669PA (en) | 2014-10-20 | 2020-12-30 | Oyster Point Pharma Inc | Methods of treating ocular conditions |
| CN109310692B (zh) | 2016-04-07 | 2022-01-25 | 奥伊斯特普安生物制药公司 | 治疗眼部病状的方法 |
| TW202019417A (zh) | 2018-07-10 | 2020-06-01 | 美商奧伊斯特普安生物製藥公司 | 治療眼部症狀之正向異位調節劑與菸鹼乙醯膽鹼受體促效劑之組合 |
| TW202019424A (zh) | 2018-07-10 | 2020-06-01 | 美商奧伊斯特普安生物製藥公司 | 治療眼部症狀之方法 |
-
2015
- 2015-10-19 SG SG10202011669PA patent/SG10202011669PA/en unknown
- 2015-10-19 PT PT158523407T patent/PT3209295T/pt unknown
- 2015-10-19 BR BR122022025737-2A patent/BR122022025737B1/pt active IP Right Grant
- 2015-10-19 EP EP15852340.7A patent/EP3209295B2/en active Active
- 2015-10-19 CN CN202010304375.2A patent/CN111956803B/zh active Active
- 2015-10-19 KR KR1020177013534A patent/KR102511955B1/ko active Active
- 2015-10-19 US US14/887,253 patent/US9532944B2/en active Active
- 2015-10-19 ES ES15852340T patent/ES2848977T5/es active Active
- 2015-10-19 DK DK20212556.3T patent/DK3848028T5/da active
- 2015-10-19 ES ES20212556T patent/ES2986830T3/es active Active
- 2015-10-19 EP EP24171017.7A patent/EP4413974A3/en active Pending
- 2015-10-19 KR KR1020237009057A patent/KR102601505B1/ko active Active
- 2015-10-19 EA EA201790893A patent/EA035335B1/ru unknown
- 2015-10-19 US US14/887,243 patent/US9504644B2/en active Active
- 2015-10-19 CN CN201580067940.5A patent/CN107106542B/zh active Active
- 2015-10-19 CA CA2965129A patent/CA2965129C/en active Active
- 2015-10-19 CN CN202010304809.9A patent/CN111956650B/zh active Active
- 2015-10-19 IL IL293188A patent/IL293188B2/en unknown
- 2015-10-19 IL IL318427A patent/IL318427A/en unknown
- 2015-10-19 US US14/887,259 patent/US9504645B2/en active Active
- 2015-10-19 BR BR112017008097-4A patent/BR112017008097B1/pt active IP Right Grant
- 2015-10-19 US US14/887,248 patent/US9597284B2/en active Active
- 2015-10-19 WO PCT/US2015/056273 patent/WO2016064759A1/en not_active Ceased
- 2015-10-19 FI FIEP20212556.3T patent/FI3848028T3/fi active
- 2015-10-19 AU AU2015336216A patent/AU2015336216B2/en active Active
- 2015-10-19 EP EP20212556.3A patent/EP3848028B9/en active Active
- 2015-10-19 PL PL20212556.3T patent/PL3848028T3/pl unknown
- 2015-10-19 PT PT202125563T patent/PT3848028T/pt unknown
- 2015-10-19 DK DK15852340.7T patent/DK3209295T4/da active
- 2015-10-19 IL IL251769A patent/IL251769B/en unknown
- 2015-10-19 SG SG11201703135XA patent/SG11201703135XA/en unknown
- 2015-10-19 JP JP2017539528A patent/JP6873906B2/ja active Active
- 2015-10-19 MY MYPI2017701382A patent/MY186870A/en unknown
- 2015-10-19 MX MX2017005064A patent/MX392383B/es unknown
-
2017
- 2017-02-01 US US15/422,382 patent/US10456396B2/en active Active
- 2017-03-31 PH PH12017500602A patent/PH12017500602A1/en unknown
- 2017-04-19 MX MX2022005888A patent/MX2022005888A/es unknown
- 2017-05-19 ZA ZA2017/03467A patent/ZA201703467B/en unknown
-
2019
- 2019-09-10 US US16/566,237 patent/US11224598B2/en active Active
-
2020
- 2020-08-06 AU AU2020213351A patent/AU2020213351B2/en active Active
- 2020-11-20 JP JP2020193269A patent/JP7257371B2/ja active Active
-
2021
- 2021-12-06 US US17/543,505 patent/US11903941B2/en active Active
-
2022
- 2022-12-20 JP JP2022202809A patent/JP7502404B2/ja active Active
-
2023
- 2023-03-23 US US18/125,551 patent/US11911380B2/en active Active
- 2023-03-23 US US18/125,562 patent/US11903943B2/en active Active
- 2023-03-23 US US18/125,517 patent/US11903942B2/en active Active
-
2024
- 2024-01-26 US US18/423,908 patent/US20240173318A1/en not_active Abandoned
-
2025
- 2025-04-03 US US19/169,817 patent/US20250235449A1/en active Pending
- 2025-04-03 US US19/169,843 patent/US12576080B2/en active Active
- 2025-04-03 US US19/169,836 patent/US20250275963A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023024574A5 (https=) | ||
| JP2021038250A5 (https=) | ||
| CA2960611C (en) | NEUROACTIVE STEROIDS, THEIR COMPOSITION AND USES | |
| Jünemann et al. | Drug bioavailability from topically applied ocular drops. Does drop size matter? | |
| US10406203B2 (en) | Ophthalmic treatment composition and vehicle for delivery of pharmaceutical substances or therapeutic agents | |
| JP2022120125A5 (https=) | ||
| JP7257371B2 (ja) | 眼の病状の治療方法 | |
| CN110075148A (zh) | 三七皂苷提取物在制备眼用药物制剂中的应用 | |
| US20200022963A1 (en) | Pharmaceutical composition comprising betahistine | |
| US20190365728A1 (en) | Pharmaceutical composition comprising betahistine | |
| CN119258116A (zh) | 一种治疗干眼的中药组合物及其制备方法和应用 | |
| JPH0977656A (ja) | 点眼用エアゾル組成物 | |
| KR20230130479A (ko) | 안구건조증 또는 마이봄샘 기능장애의 예방, 개선, 또는 치료용 조성물 | |
| Felicilda Reynaldo et al. | Evidence-Based Pharmacotherapy for Dry Eye Disease, Part 2 | |
| Elliott et al. | Varenicline Nasal Spray (Tyrvaya) | |
| Garrigue et al. | A comparative study of latanoprost-cationic emulsion (Catioprost) and latanoprost aqueous solution (Xalatan) in preclinical efficacy and safety models | |
| US20200093887A1 (en) | Ophthalmic treatment composition and vehicle for delivery of pharmaceutical substances or therapeutic agents | |
| HK40114233A (zh) | 包含倍他司汀的鼻内组合物 | |
| Himi et al. | and Reports | |
| JPH04327540A (ja) | カルシトニン含有医薬 | |
| US20070071835A1 (en) | Administering pharmaceutical compositions to the mammalian central nervous system |